Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer

Twelves Christopher, William J. Gradishar, Joyce A. O'Shaughnessy, Betsy Bramsen, Robert H. Lurie

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Quality of life is accepted as an important consideration in the management of patients with metastatic breast cancer, which remains incurable. Recent clinical trials of newer agents, such as eribulin and trastuzumab emtansine, have incorporated quality of life analyses. Quality of life is impacted by multiple patient-related, disease-related, and treatment-related factors. Therapies most beneficial for maintaining or improving quality of life include those that can effectively reduce tumor burden and tumor-related symptoms, but have toxicity profiles that are well tolerated and easily managed. Overall outcomes of patients with metastatic breast cancer improve when therapy is focused not only on the disease itself, but also on the goals of minimizing diseaserelated and treatment-related symptoms. A paradigm shift now reflected in major guidelines is the incorporation of palliative care strategies earlier in the course of metastatic disease management. The selection and sequence of treatments should be made in cooperation with the patient and after consideration of her particular priorities.

Original languageEnglish (US)
JournalClinical advances in hematology & oncology : H&O
Issue number2
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this